Candida albicans is a semi-ubiquitous pathobiont that is known to significantly impact human health and wellbeing, causing a significant financial strain on the medical system. Due to increasing antifungal resistance, there is a growing need for novel fungal therapeutics to treat diseases caused by this fungus. The development and use of Live Biotherapeutic Products (LBPs) is an innovative and novel approach to potentially treating Candidiasis and other comorbidities associated with C. albicans infection. To evaluate their anti-pathogenic efficacy, it is necessary to understand the underlying mechanisms involved, via the use of biomimetic cell models. In this study, six LBPs were chosen to investigate their competitive inhibitory effect against C. albicans using a co-culture of Caco-2 cells and mucous-secreting HT29-MTX cells to mimic human gut epithelium. The LBP strains were supplied by Servatus Biopharmaceuticals and identified as SVT 01D1, SVT 04P1, SVT 05P2, SVT 06B1, SVT 07R1 and SVT 08Z1. Five out of the six LBPs showed a significant reduction in the adhesion of C. albicans and all six LBPs reduced C. albicans invasion in the co-culture cells to varying degrees. There was no significant difference between co-inoculation of C. albicans with the LBPs or pre-inoculation of LBPs before the addition of C. albicans. The potential of these LBPs as novel anti-fungal therapeutics for the treatment of C. albicans diseases can be further documented in clinical trials.

白色念珠菌是一种半普遍存在的病原体，众所周知，它会严重影响人类的健康和福祉，给医疗系统造成重大的经济压力。由于抗真菌耐药性的增加，越来越需要新的真菌疗法来治疗由这种真菌引起的疾病。活生物治疗产品 (LBP) 的开发和使用是一种创新和新颖的方法，可潜在治疗念珠菌病和其他与白色念珠菌感染相关的合并症。为了评估它们的抗病原体功效，有必要通过使用仿生细胞模型来了解所涉及的潜在机制。在这项研究中，选择了六种 LBP 来研究它们对白色念珠菌的竞争性抑制作用使用 Caco-2 细胞和分泌粘液的 HT29-MTX 细胞的共培养来模拟人类肠道上皮。LBP 菌株由 Servatus Biopharmaceuticals 提供，并鉴定为 SVT 01D1、SVT 04P1、SVT 05P2、SVT 06B1、SVT 07R1 和 SVT 08Z1。六个 LBP 中有五个显示白色念珠菌的粘附显着减少，所有六个 LBP 都不同程度地减少了共培养细胞中的白色念珠菌入侵。白色念珠菌与 LBP共同接种或在添加白色念珠菌之前预接种 LBP之间没有显着差异。这些 LBP 作为治疗白色念珠菌的新型抗真菌药物的潜力 疾病可以在临床试验中进一步记录。